Shanghai Universal Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
October 26, 2022 at 01:35 pm IST
Share
Shanghai Universal Biotech Co.,Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 861.79 million compared to CNY 792.98 million a year ago. Revenue was CNY 861.79 million compared to CNY 792.98 million a year ago.
Net income was CNY 79 million compared to CNY 79.32 million a year ago. Basic earnings per share from continuing operations was CNY 0.91 compared to CNY 1.22 a year ago. Diluted earnings per share from continuing operations was CNY 0.91 compared to CNY 1.22 a year ago.
Shanghai Universal Biotech Co Ltd is a China-based company mainly engaged in the supply of life science reagent products. The Company is also engaged in the supply of life science instruments and consumables and comprehensive technical services. The products supplied by the Company are mainly third-party brand products, supplemented by independent brand products. The life science reagents mainly include immunological reagents based on antibodies and antibody related reagents, as well as molecular biology reagents, cell biology reagents and biochemical reagents. The life science instruments and consumables include detection and analysis and sample preparation. The comprehensive technical services include experimental services, technical support services and other services.